MRI READING ROOM · SESSION ACTIVE · TOPIC: MULTIPLE SCLEROSIS · REF: AAN / MSIF / FDA
The Myelin Atlas Neurology reference · U.S. edition
Neurology · Autoimmune demyelinating

In MS, the immune system attacks myelin. Every symptom follows from which pathway lost its insulation.

Roughly 1 million American adults live with multiple sclerosis, and the treatment landscape has transformed over the past 15 years — from a handful of injectable drugs to more than 20 disease-modifying therapies with very different efficacy and safety profiles. Getting the diagnosis right and matching the therapy to the disease course is what determines long-term outcome.

16 min read
McDonald 2017 aligned
4 courses · 4 DMT classes
1M+
U.S. adults live with MS — roughly 1 in 300, and the number is rising with better diagnosis.
3:1
Female-to-male ratio — MS is 2 to 3 times more common in women.
20–40
Typical age of onset — MS usually begins in early adulthood, though pediatric and late-onset forms exist.
85%
Begin with RRMS — most patients later transition to secondary progressive MS.
Section 01 · The mechanism

What MS does to the central nervous system — and why symptoms vary so widely.

Multiple sclerosis is an autoimmune disease in which the immune system mistakenly attacks the myelin sheath — the fatty insulation that wraps around nerve fibers in the brain and spinal cord. Myelin is what allows electrical signals to travel quickly and reliably from one neuron to the next. When it is damaged, signals slow, become uncoordinated, or fail entirely.

The attack is driven by T lymphocytes that cross the blood-brain barrier and recognize myelin proteins as targets. This triggers inflammation, demyelination, and — over time — loss of the underlying axons themselves. The inflammation produces the characteristic MRI lesions — bright spots on T2/FLAIR sequences — which appear in the white matter, often in periventricular, juxtacortical, infratentorial, or spinal cord locations. These four locations make up the "space" component of the diagnostic criteria.

Because myelin wraps every long pathway in the nervous system, symptoms depend on which pathways are affected. Optic nerve involvement produces optic neuritis — pain with eye movement and vision loss. Spinal cord involvement produces sensory changes, weakness, and bowel or bladder dysfunction. Brainstem involvement produces double vision, vertigo, or facial numbness. Cerebellar involvement produces tremor and imbalance. Over decades, the accumulation of these deficits produces the disability that MS is most feared for.

The disease is driven by two overlapping processes. Inflammation produces the discrete attacks (relapses) that characterize the early disease course. Neurodegeneration produces the slow, steady accumulation of disability that dominates later stages. Modern disease-modifying therapies target the inflammatory component — which is why they work best when started early, before significant neurodegeneration has accumulated.

Section 02 · Disability scale

The EDSS — how disability is measured in MS.

The Expanded Disability Status Scale (EDSS) is the most widely used measure of MS disability. It ranges from 0 (normal neurological exam) to 10 (death from MS), with half-point increments at higher scores.

EDSS scale · key ranges
Expanded Disability Status Scale · Kurtzke
0— 2.5

Minimal disability. Normal or near-normal neurological exam. Patient fully ambulatory, may have minor sensory or visual symptoms that do not limit function.

3— 4.5

Moderate disability. Fully ambulatory without aid, but with significant functional limitations. May include weakness, spasticity, or fatigue that interferes with daily activities.

5— 6.5

Ambulatory impairment. Requires assistance, a cane, or crutches to walk 100–200 meters. Work and daily activities substantially limited.

7— 9.5

Severe disability. Restricted to wheelchair, then bed. Retains ability to communicate and eat. Requires full assistance for daily care.

10

Death from complications of MS. Rarely reached in the modern treatment era.

What EDSS does not capture. EDSS is heavily weighted toward walking ability and underweights cognitive dysfunction, fatigue, depression, pain, and upper-limb function — all of which have a major impact on quality of life. Modern clinical trials increasingly use composite measures (like NEDA-3 — "no evidence of disease activity" — combining relapses, MRI lesions, and disability progression) alongside EDSS. When discussing treatment goals, the conversation should be broader than a single number.
Section 03 · Disease courses

Four clinical patterns — and how the treatment approach differs.

MS is classified into clinical courses based on the pattern of relapses and progression over time. The classification guides treatment selection and prognosis.

RRMS

Relapsing-remitting MS

Discrete attacks (relapses) with partial or complete recovery, then periods of stability. Most patients begin here. DMTs are highly effective at reducing relapse rate and delaying progression.

SPMS

Secondary progressive MS

Develops after an initial RRMS phase — relapses become less frequent but disability steadily accumulates. Approximately half of RRMS patients transition within 15–20 years. Treatment focus shifts to slowing progression.

PPMS

Primary progressive MS

Disability accumulates steadily from onset without distinct relapses. Typically presents later in life and affects men and women equally. Ocrelizumab is the only DMT approved specifically for PPMS, though others are used off-label.

PRMS

Progressive-relapsing MS

Progressive from onset with occasional superimposed relapses. Now generally considered a variant of PPMS rather than a distinct category. Older classification systems used this term; modern practice has largely abandoned it.

Section 04 · Diagnosis

McDonald criteria — dissemination in space and time.

The McDonald criteria (last revised in 2017) define how MS is diagnosed. The core principle is that MS requires evidence of lesions in multiple parts of the CNS (space) occurring at multiple points in time (time) — without an alternative explanation.

Clinical attacks Additional evidence required Interpretation
≥ 2 attacks None (clinical diagnosis) MS can be diagnosed clinically if two attacks separated in space and time are documented, with objective findings on exam.
2 attacks, one clinical MRI evidence of dissemination in space OR positive oligoclonal bands MRI showing lesions in ≥ 2 typical locations — periventricular, juxtacortical, infratentorial, or spinal cord.
1 attack, two findings MRI evidence of dissemination in time New T2 or gadolinium-enhancing lesion on follow-up MRI compared with baseline.
1 attack only MRI evidence of both space and time The most common modern diagnostic scenario for patients presenting with a first clinical event.
PPMS pattern 1 year of progression + 2 of 3: brain lesions, spinal cord lesions, positive CSF Specific pathway for primary progressive MS, which does not present with discrete attacks.

MRI sequences that matter. T2/FLAIR sequences show the total burden of lesions — both old and active. Gadolinium-enhanced T1 sequences show lesions that are currently inflamed (active) — the contrast leaks through a disrupted blood-brain barrier. A study showing new or enhancing lesions compared with a prior scan establishes dissemination in time. Cerebrospinal fluid analysis for oligoclonal bands — present in about 90 percent of MS patients — provides supporting evidence when MRI is equivocal, and in the 2017 criteria can substitute for dissemination in time in some cases.

What MS is not. Many conditions mimic MS on MRI, including migraine (nonspecific white matter spots), small vessel disease, neuromyelitis optica (NMO — now called NMOSD), MOG antibody disease, and systemic autoimmune diseases. Testing for anti-aquaporin-4 antibodies (NMO) and MOG antibodies is now standard when the clinical or imaging picture is atypical, because these conditions require different treatment.

Section 05 · Disease-modifying therapies

Four classes of DMT — from platform injectables to high-efficacy infusions.

More than 20 disease-modifying therapies are approved for MS in the United States. They differ substantially in route, efficacy, monitoring burden, and risk profile. The choice depends on disease activity, prognosis, patient preference, and reproductive plans.

Platform injectables — the original DMTs
Self-injection · daily to weekly

Interferon beta formulations and glatiramer acetate were the first DMTs approved for MS, starting in the 1990s. They modulate the immune response rather than suppressing it broadly. Reduce relapse rates by about 30 percent and have an excellent long-term safety record.

Given by self-injection — daily, every other day, or weekly depending on the formulation. Side effects include injection-site reactions and, for interferons, flu-like symptoms. Increasingly considered inadequate for highly active disease, but still appropriate for mild presentations.

Examplesinterferon beta-1a · interferon beta-1b · peginterferon beta-1a · glatiramer acetate
Oral DMTs — the pills
Once or twice daily

Since 2010, several oral DMTs have been approved. They offer convenience and moderate-to-good efficacy, but each requires specific monitoring. Fingolimod and other S1P receptor modulators require first-dose cardiac monitoring (bradycardia), ophthalmic monitoring (macular edema), and liver monitoring. Dimethyl fumarate requires monitoring for lymphopenia.

Teriflunomide is teratogenic and requires contraception and a washout protocol. Cladribine is given as two short courses per year, then nothing — an appealing option for some patients. Atypical PML (progressive multifocal leukoencephalopathy) is a rare but serious risk with several DMTs.

Examplesfingolimod · dimethyl fumarate · teriflunomide · cladribine · siponimod · ozanimod · ponesimod
Infusion DMTs — high-efficacy monoclonal antibodies
Every 1–6 months · infusion center

Natalizumab is highly effective (reduces relapse rate by ~68%) but carries a risk of PML that increases with JC virus antibody positivity and treatment duration. Ocrelizumab, ofatumumab, and rituximab deplete B cells and are among the most effective DMTs available — ocrelizumab is the only DMT approved for primary progressive MS.

Alemtuzumab is a two-year pulsed treatment with the highest efficacy of any approved DMT, but carries serious autoimmune risks (thyroid disease, ITP, kidney disease) requiring lifelong monitoring. Most of these are used as first-line therapy in highly active MS.

Examplesnatalizumab · ocrelizumab · ofatumumab · rituximab (off-label) · alemtuzumab
Biosimilars & the treatment strategy
Evolving landscape

Biosimilars to several MS DMTs have entered the U.S. market, increasing access and reducing cost. As patents expire on additional DMTs, this trend will continue. Efficacy is comparable to the reference product in approved biosimilars.

Treatment strategy has shifted toward early high-efficacy therapy. Trials such as TREAT-MS and DELIVER-MS are comparing "escalation" (starting with a lower-efficacy drug and switching if it fails) vs. "early high-efficacy" (starting with the strongest drug). Available evidence increasingly favors early high-efficacy for patients with active disease.

The goal has changed. For decades, the goal of MS treatment was "reduce relapses." The modern goal is NEDA-3 — no evidence of disease activity — meaning no relapses, no new or enlarging MRI lesions, and no confirmed disability progression. Achieving NEDA-3 in the first few years of treatment predicts better long-term outcomes. This is why DMT selection is no longer "start with the safest and escalate if needed" for everyone — many specialists now recommend starting with a high-efficacy DMT for patients with active disease.

Not all patients need a DMT. Rare patients with very mild disease and no MRI activity might reasonably defer treatment with close monitoring. But deferred treatment should be an explicit, discussed choice with a neurologist, not a passive one. Most evidence supports early treatment for the majority of newly diagnosed patients.

Section 06 · Clinical features

Six symptoms that are characteristic — and often misunderstood.

Optic neuritis

Inflammation of the optic nerve — pain with eye movement, blurred vision, color desaturation (especially red), and a central scotoma. Often the first symptom of MS. Vision typically recovers over weeks, sometimes with residual color deficit.

Lhermitte's sign

An electric-shock sensation running down the spine and into the limbs when the neck is flexed. Caused by a lesion in the cervical spinal cord. Not dangerous, but highly characteristic of MS and cervical cord involvement.

Uhthoff's phenomenon

Transient worsening of symptoms with increased body temperature — exercise, hot showers, fever, hot weather. Caused by slowed conduction in already-demyelinated fibers. Not a relapse, and it resolves as the body cools.

MS hug (band-like sensation)

A tight, constricting sensation around the trunk or limbs. Caused by spinal cord lesions affecting sensory pathways. Often described as a corset or band around the chest or abdomen. Can be persistent or paroxysmal.

Fatigue

The single most common MS symptom, affecting up to 80 percent of patients. Not ordinary tiredness — a heavy, lassitude-like exhaustion that worsens with heat and does not improve with rest. Distinct from depression and from sleep disorders.

Cognitive dysfunction

Present in up to half of MS patients even early in the disease. Most commonly affects processing speed, working memory, and multitasking. Frequently underrecognized and often misattributed to depression or fatigue.

Section 07 · Relapse management

Acute relapses — and how they are treated.

ACUTE RELAPSE · TREATMENT PLAN

A relapse lasts at least 24 hours, is not caused by fever or infection, and produces new or worsening neurological symptoms.

1

Confirm it is a relapse

Rule out infection, fever, heat, and metabolic causes — these can mimic a relapse. A true relapse lasts more than 24 hours and is not explained by another cause.

2

Assess functional impact

Mild sensory symptoms may not need treatment. Relapses that affect vision, walking, bowel or bladder function, or cognition are typically treated promptly.

3

High-dose corticosteroids

IV methylprednisolone 1 g daily for 3–5 days is standard. Oral prednisone at equivalent doses is an acceptable alternative. Corticosteroids shorten the relapse but do not change long-term disability.

4

Consider plasma exchange (PLEX)

For severe relapses that do not respond to corticosteroids after 1–2 weeks, plasma exchange may be effective. Reserved for serious cases with significant disability.

Treating a relapse does not change the disease. Corticosteroids shorten the current attack; they do not slow the underlying MS process or prevent future relapses. That is what disease-modifying therapy is for. A patient on a DMT who has a relapse should have their treatment reviewed — the DMT may need to be escalated.

Section 08 · What to watch for

Features that require prompt evaluation.

Evaluate urgently

If any of these appear, contact the care team right away.

New focal neurological symptoms. Sudden weakness, sensory loss, speech difficulty, or vision loss. Could be a relapse — or could be a stroke. Both require prompt evaluation.
New onset of fever with neurological symptoms. Infection can mimic a relapse or trigger one. Fever during DMT therapy may also indicate a serious drug-related infection (especially with natalizumab, alemtuzumab, or fingolimod).
New confusion, personality change, or seizures on a DMT. Suggests possible PML (with natalizumab, fingolimod, or others) or drug-related infection. Requires urgent brain MRI and specialist input.
Signs of autoimmune complications on alemtuzumab. New fatigue, hair thinning, weight change, easy bruising, or blood in urine can indicate thyroid disease, ITP, or kidney disease — all more common after alemtuzumab treatment.
New rash, severe allergic reaction, or unexplained organ dysfunction after any infusion DMT. Requires prompt evaluation for drug reaction. Do not continue the medication without clearance.
Bowel or bladder dysfunction that is new or worsening. Especially retention or incontinence — often indicates spinal cord involvement and needs evaluation for relapse or other cause.
Section 09 · Access & affordability

MS medication is expensive. Coverage is available — with planning.

MS disease-modifying therapies are among the most expensive chronic medications in medicine. Brand-name DMTs can cost $60,000 to $120,000 per year without insurance, and while generic and biosimilar versions of the original platform injectables (interferons, glatiramer) have significantly reduced the cost of those drugs, the newer high-efficacy therapies remain brand-only and expensive.

In practice, most commercially insured patients pay a manageable copay through manufacturer copay assistance programs. Every major DMT manufacturer offers these programs, and they typically reduce the patient's out-of-pocket cost to $0 or near $0 for commercially insured patients. Patients on Medicare, Medicaid, or government insurance may face different rules, because manufacturers cannot legally provide copay assistance to those programs — but patient assistance foundations (like the HealthWell Foundation, PAN Foundation, and Patient Advocate Foundation) provide grants for the same purpose. Every specialty pharmacy that dispenses a DMT has staff whose job is to help navigate these programs.

What still varies at the pharmacy counter for generics and biosimilars: the same drug can cost substantially different amounts at different pharmacies. A live prescription price comparison shows the current range in about two minutes, and the same logic applies to every generic on a patient's list. For a first-time online refill of a generic medication, the process is documented step by step in this how to order prescriptions online guide — prescription first, licensed seller second, small first order third. Note that infusion DMTs must be administered at a clinic or infusion center, and cannot be dispensed by an online pharmacy.

Before filling from any seller — online or local — verify them. A working VIPPS seal that resolves to a live NABP record, a real U.S. street address, and a prescription requirement that cannot be waived. A transparency page like this one about Metformin4You is a reasonable example of the standard to expect.

Section 10 · Questions

Five asked most often at the MS clinic.

Q·01 What is multiple sclerosis? +
Multiple sclerosis is an autoimmune disease in which the immune system attacks the myelin sheath that insulates nerve fibers in the central nervous system. Loss of myelin disrupts electrical signaling and produces a wide range of neurological symptoms depending on which pathways are affected. It is a chronic, typically progressive condition affecting roughly one million American adults.
Q·02 How is multiple sclerosis diagnosed? +
MS is diagnosed using the McDonald criteria, which combine clinical attacks with MRI evidence of lesions disseminated in space and time, and in some cases cerebrospinal fluid oligoclonal bands. A diagnosis requires at least two clinical attacks separated in time and space, or a first attack with MRI evidence of dissemination confirmed on follow-up imaging.
Q·03 What are the four disease courses of MS? +
Relapsing-remitting MS (RRMS) is the most common, involving discrete attacks followed by recovery. Secondary progressive MS (SPMS) develops when RRMS transitions to steady progression. Primary progressive MS (PPMS) involves progression from onset without distinct relapses. Progressive-relapsing MS (PRMS) is now generally considered a variant of PPMS. About 85 percent of patients begin with RRMS.
Q·04 Are disease-modifying therapies effective? +
Yes. Randomized trials show that disease-modifying therapies reduce relapse rates by 30 to 70 percent depending on the drug, and reduce new MRI lesion formation substantially. Higher-efficacy drugs (natalizumab, ocrelizumab, alemtuzumab) reduce relapses more than first-line injectables but carry greater risks and require closer monitoring. Early treatment is associated with better long-term outcomes.
Q·05 How is an acute MS relapse treated? +
Acute relapses that cause significant functional impairment are typically treated with high-dose intravenous or oral corticosteroids — usually 1 gram of methylprednisolone daily for 3 to 5 days. Corticosteroids shorten relapses but do not change long-term disability. Plasma exchange may be used for severe relapses that do not respond to steroids.
◆ Sources & Verification
This reference is aligned with public clinical guidance from the National Multiple Sclerosis Society, the American Academy of Neurology (AAN) MS Clinical Practice Guidelines, the National Institute of Neurological Disorders and Stroke (NIH), the Multiple Sclerosis International Federation (MSIF), and the U.S. Food and Drug Administration's BeSafeRx program. Drug-label information draws on the National Library of Medicine's DailyMed database and MedlinePlus. Pharmacy verification follows the NABP VIPPS program.
◆ Before the next refill

The right DMT matters. So does not overpaying for it.

Disease-modifying therapies are among the most expensive chronic medications, and the same drug can cost dramatically different amounts at different pharmacies. A two-minute comparison across licensed U.S. sellers is a useful habit to build. Begin with the current Metformin price comparison as a live demonstration of how wide the spread runs.

Open the price comparison